Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.

In a real-world setting, PCSK9i treatment was associated with increased reporting of mild hyperglycaemia, but not diabetes. While initial monitoring is warranted, the favourable glycaemic safety profile compared to statins supports their essential role in the management of lipid disorders.